Publications by authors named "Munjal Mehta"
Repurposing therapeutic agents with existing clinical data is a common strategy for developing radiation countermeasures. IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling. Here, we evaluated IEPA's radiomitigative efficacy in the hematopoietic subsyndrome of acute radiation syndrome (H-ARS) using total-body irradiation (TBI) models in C57BL/6J mice and WAG/RijCmcr rats, applying various posology schemes and introducing syringe feeding of the IEPA formulation in the pudding.
View Article and Find Full Text PDFArticle Synopsis
- - The study addresses the public health concern of mass casualty disasters involving radiation, noting that survivors of high radiation exposure (8-10 Gy) face delayed health issues, particularly renal failure.
- - Researchers established the WAG/RijCmcr rat model to test medical countermeasures (MCM) for acute hematologic radiation syndrome (H-ARS) and found that the FDA-approved drug pegfilgrastim significantly improved survival rates in rats post-exposure.
- - Findings indicated that while peg-GCSF treatment enhanced short-term survival, survivors of higher TBI doses experienced a notable decline in long-term survival and renal function, highlighting the need for ongoing monitoring and care for these individuals.
A quality by design (QbD) approach was used for a polyvinyl alcohol (PVA)-based coating to develop a 'look-alike' placebo tablet, which can match the glossiness (shine) of an innovator tablet. Critical coating parameters such as exhaust temperature, drying capacity, solid concentration in coating dispersion, and plasticizer concentration were studied using a full factorial design of experiment DoE). Total of 20 experimental coating runs was executed on a pilot scale using a perforated pan coater.
View Article and Find Full Text PDF